Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 9/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.38 |
| ▸ | FLT4 | P35916 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19775531 | 0.90 | PTPRB (0.48) | VCPPTPRBFLT1FLT4KDR | |
| SCHEMBL467924 | 0.88 | PTPRB (0.57) | VCPPTPRB | |
| SCHEMBL468300 | 0.88 | PTPRB (0.57) | VCPPTPRB | |
| SCHEMBL686835 | 0.86 | MAOB (0.42) | VCPPTPRBFLT1FLT4KDR | |
| SCHEMBL500482 | 0.86 | MAOB (0.42) | VCPPTPRBFLT1FLT4KDR | |
| SCHEMBL20059857 | 0.84 | PTPRB (0.44) | PTPRBKDM4ELMNAMAPTALDH1A1 | |
| SCHEMBL20810397 | 0.83 | PTPRB (0.42) | VCPPTPRBFLT1FLT4KDR | |
| SCHEMBL20059917 | 0.82 | PTPRB (0.42) | PTPRBLMNAMAPTALDH1A1 | |
| SCHEMBL468110 | 0.80 | PTPRB (0.56) | VCPPTPRB | |
| SCHEMBL468107 | 0.80 | PTPRB (0.56) | VCPPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-07-02 | — | — | US | disclosed |
| EP-3607821-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-2967066-B1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2451279-B1 | BENZOSULFONAMIDE DERIVATIVES, COMPOSITIONS THEREOF, AND THEIR USE IN PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2385763-B1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AERPIO THERAPEUTICS INC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2624916-B1 | THIADIAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF OCULAR EDEMA | AERPIO THERAPEUTICS INC (US) | 2018-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | VCP 3196/4885PTPRB 551/4885FLT1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.